Hyperpigmentation Disorders Treatment Market to Teach Worth of US$ 7,225.6 Mn by 2026

The global hyperpigmentation disorders treatment market was pegged at US$ 3,947.3 Mn in 2017. It is projected to clock CAGR of more than 7.2% during the forecast period of 2018 to 2026. This is projected to reach worth of US$ 7,225.6 Mn by 2026

Expanding Data on Diagnosis, Evaluation, and Treatment Shapes Value Chain of Hyperpigmentation Disorders Treatment

The pigmentation biology has made considerable strides over the decades, anchored broadly by evolution, developmental biology, and genetics. A significant percentage of all dermatological consultations in a number of countries around the world is motivated by cutaneous hyperpigmentations, with most common complaints between 15 and 30 years of age, regardless of color, gender, and skin.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111996

Hyperpigmentations are a group of diseases that can be acquired or congenital, and the symptoms are associated with alterations in the melanin pigment. Key group of disorders that have been propelling revenues in the hyperpigmentation disorders treatment market are postinflammatory hyperpigmentation, solar lentigines, melasma, ephelides (or freckles), and macules. Various treatments either as standalone or a combination of any two or more have been researched for the treatment of hyperpigmentation. Melasma and vitiligo are by far the most common disorders. Most of the conditions appear to be benign but are aesthetically distressing condition.

The global hyperpigmentation disorders treatment market was pegged at US$ 3,947.3 Mn in 2017. It is projected to clock CAGR of more than 7.2% during the forecast period of 2018 to 2026. This is projected to reach worth of US$ 7,225.6 Mn by 2026. The growing incidence of pigmentation disorders in the elderly is a key driver for prospects in the market.

Major treatment types that stir revenue generation in the global hyperpigmentation disorders treatment market are topical drugs, laser therapy, chemical peels, phototherapy, and microdermabrasion.

Melasma Highly Lucrative Segment in Hyperpigmentation Disorders Treatment Market

A number of histological and immunohistochemical studies have expanded the researchers’ understanding of the pathogenesis of melasma, thus enriching the landscape of the hyperpigmentation disorders treatment market. Some of the key treatment avenues are topical hydroquinone (HQ), retinoic acid (RA), glycolic acid (GA) (double combination), and topical corticosteroid (triple combination) in double as well as triple combinations. On the back of R&D on these treatment avenues, the melasma was the leading disease indication segment in 2017.

View full report@ https://qyresearchmedical.com/report/hyperpigmentation-disorders-treatment-market-treatment-type-topical-drugs-laser-therapy-chemical-peels-phototherapy-microdermabrasion-disease-indication-melasma-post-inflammatory-hyperpigmentation-solar-018-2030/111996

It is predominant in women but is also significant in men across all ethnic and racial groups. This is prevalent in populations exposed to UV rays. In addition to UV exposure, various causative factors are involved. The demand for treatments is high in Asia Pacific, notably in Asian nations. A number of studies have been done to assess the demand in China, India, and Korea. Several studies have been found high prevalence of hyperpigmentation disorders in India, mainly due to prevalent sun-exposed environments. In the country, melasma can be attributed to or exacerbated by UV exposures. Upcoming therapies for melasma are likely to target prospects in this hyperpigmentation disorders treatment market and might open lucrative avenues. Advances in molecular genetics of human pigmentation disorders are enriching the landscape.

Other causes are estrogen levels, genetic predisposition, and phototoxic drugs; genetic predisposition might also play a role in causing melasma.

Effectiveness of Laser Therapies in Hyperpigmentation Disorders Treatment Market Underpin High Acceptance Among Patients

The demand for treatments of post-inflammatory hyperpigmentation (PIH) is a key accelerant for new avenues in the hyperpigmentation disorders treatment market. The prevalence of people with higher skin phototypes. Despite a large body of studies on PIH pathogenesis, currently there is an unmet need, which is expected to be capitalized by emerging and established players in the global hyperpigmentation disorders treatment market. A number of formulations such as hydroquinone, tretinoin, and dexamethasone are being explored to bridge this gap.

The growing effectiveness of laser therapies in the treatment of hyperpigmentation, such as dark circles or periorbital hyperpigmentation (POH), has generated massive revenue potential in the hyperpigmentation disorders treatment market. The patient’s acceptance of laser therapies has increased in recent years. Key of them are QS ruby laser-based treatments. The prevalent use of fractional laser photothermolysis in the treatment of disorders is a key factor bolstering the sales revenues in the hyperpigmentation disorders treatment market.

Over the years, new data on hyperpigmentation disorders have emerged, and still continue to enrich the landscape of the hyperpigmentation disorders treatment market. Subsequently, systemic use of corticosteroids, griseofulvin, antibiotics, isoniazid, antimalarials, psychotherapy, and phototherapy have boosted the hyperpigmentation disorders market.

Apart from the laser therapy, topical depigmenting agents have been extensively publicised in the hyperpigmentation disorders treatment market. These drugs aim at reducing the amount of melanin content. Topical drugs have been publicised in the treatment of cervical idiopathic poikiloderma or poikiloderma of Civatte (PC). The chronic nature of PC is a key driver for the need.

Various dermatology companies are harnessing the potential of several topical agents in newly launched products in the hyperpigmentation disorders treatment market. Of note, they have extensively marketed hydroquinone (HQ), a hydroxyphenol, for the treatment of PIH. In recent years, more studies have been done particularly in relation to developing topical retinoids for the treatment of melasma and actinic lentigines. Popular agents in some of the recent array of products in the market include soy extracts, mulberroside F, licorice extract, N-acetyl glucosamine, resveratrol, rucinol,niacinamide, and dioic acid.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111996/2900

Asia Pacific Expected to Gain Share in Hyperpigmentation Disorders Treatment Market

The various regional markets are Europe, North America, Asia Pacific, the Middle East & Africa, and Latin America. Of these, Asia Pacific held a major share of the global hyperpigmentation disorders treatment market in 2017. The Asia Pacific hyperpigmentation disorders treatment market is anticipated to gain share by the end of the forecast period. New revenue streams are expected to emerge from the economies of the Middle East, Latin America, and Africa.

Some of the key players in the hyperpigmentation disorders treatment market are Vivier Pharma, Obagi Cosmeceuticals LLC, RXi Pharmaceuticals Corporation, EpiPharm AG, Pierre Fabre, SkinCeuticals, Galderma S.A., ALLERGAN, and Bayer AG.

The global hyperpigmentation disorders treatment market has been segmented as follows:

Treatment Type

  • Topical Drugs
  • Laser Therapy
  • Chemical Peels
  • Microdermabrasion
  • Phototherapy
  • Others

Disease Indication

  • Melasma
  • Post-inflammatory Hyperpigmentation
  • Solar Lentigines
  • Others

End-user

  • Hospitals
  • Aesthetic Clinics & Dermatology Centers
  • Others

Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Australia & New Zealand
  • India
  • Rest of Asia-pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Israel
  • Rest of Middle East & Africa

TABLE OF CONTENT

Section 01: Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights

Section 02: Assumptions and Research Methodology

2.1 Assumptions
2.2 Research Methodology

Section 03: Executive Summary
3.1 Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) and Distribution by Geography, 2017 and 2026
3.2 Global Hyperpigmentation Disorders Treatment Market Snapshot, 2017
3.3 Global Hyperpigmentation Disorders Treatment Market: Opportunity Map

Section 04: Market Overview
4.1 Overview
4.2 Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, 2016–2026
4.3 Global Hyperpigmentation Disorders Treatment Market Outlook
4.4 Global Hyperpigmentation Disorders Treatment Market: Porter’s Five Forces Analysis
4.5 Hyperpigmentation Disorders Treatment Market: Pipeline Analysis
4.6 Key Partnership & Acquisitions
4.7 Policies and Regulations: By Region
4.8 Disease Prevalence and Incidence Rate Globally
4.9 Global Hyperpigmentation Disorders Treatment Market: Pricing Assessment

Section 05: Market Dynamics
5.1 Drivers
5.2 Restraints
5.3 Opportunity Analysis
5.4 Opportunities
5.5 Trends

Section 06: Global Hyperpigmentation Disorders Treatment Market Analysis, by Treatment Type
6.1 Introduction
6.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Treatment Type
6.3 Hyperpigmentation Disorders Treatment Market Analysis, by Treatment Type
6.3.1 Topical Drugs
6.3.2 Laser Therapy
6.3.3 Chemical Peels
6.3.4 Microdermabrasion
6.3.5 Phototherapy
6.3.6 Others
6.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment Type

Section 07: Global Hyperpigmentation Disorders Treatment Market Analysis, by Disease Indication
7.1 Introduction
7.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Disease Indication
7.3 Hyperpigmentation Disorders Treatment Market Analysis, by Disease Indication
7.3.1 Melasma
7.3.2 Post-inflammatory Hyperpigmentation
7.3.3 Solar Lentigines
7.3.4 Others
7.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Disease Indication

Section 08: Global Hyperpigmentation Disorders Treatment Market Analysis, by End-user
8.1 Introduction
8.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by End-user
8.3 Hyperpigmentation Disorders Treatment Market Analysis, by End-user
8.3.1 Hospitals
8.3.2 Aesthetic Clinics & Dermatology Centers
8.3.3 Others
8.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by End-user

Section 09: Global Hyperpigmentation Disorders Treatment Market Analysis, by Region
9.1 Global Hyperpigmentation Disorders Treatment Market Snapshot, by Country
9.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Region
9.3 Hyperpigmentation Disorders Treatment Market Forecast, by Region
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Latin America
9.3.5 Middle East & Africa
9.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Region

Section 10: North America Hyperpigmentation Disorders Treatment Market Analysis
10.1 Key Findings
10.2 North America Hyperpigmentation Disorders Treatment Market Overview
10.3 North America Market Value Share Analysis, by Treatment Type
10.4 North America Market Forecast, by Treatment Type
10.4.1 Topical Drugs
10.4.2 Laser Therapy
10.4.3 Chemical Peels
10.4.4 Microdermabrasion
10.4.5 Phototherapy
10.4.6 Others
10.5 North America Market Value Share Analysis, by Disease Indication
10.6 North America Market Forecast, by Disease Indication
10.6.1 Melasma
10.6.2 Post-inflammatory Hyperpigmentation
10.6.3 Solar Lentigines
10.6.4 Others
10.7 North America Market Value Share Analysis, by End-user
10.8 North America Market Forecast, by End-user
10.8.1 Hospitals
10.8.2 Aesthetic Clinics & Dermatology Centers
10.8.3 Others
10.9 Market Analysis, by Country
10.10 Market Value Share Analysis, by Country
10.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
10.11.1 U.S.
10.11.2 Canada
10.12 Market Attractiveness Analysis
10.12.1 By Treatment Type
10.12.2 By Disease Indication
10.12.3 By End-user
10.12.4 By Country

Section 11: Europe Hyperpigmentation Disorders Treatment Market Analysis
11.1 Key Findings
11.2 Europe Hyperpigmentation Disorders Treatment Market Overview
11.3 Europe Market Value Share Analysis, by Treatment Type
11.4 Europe Market Forecast, by Treatment Type
11.4.1 Topical Drugs
11.4.2 Laser Therapy
11.4.3 Chemical Peels
11.4.4 Microdermabrasion
11.4.5 Phototherapy
11.4.6 Others
11.5 Europe Market Value Share Analysis, by Disease Indication
11.6 Europe Market Forecast, by Disease Indication
11.6.1 Melasma
11.6.2 Post-inflammatory Hyperpigmentation
11.6.3 Solar Lentigines
11.6.4 Others
11.7 Europe Market Value Share Analysis, by End-user
11.8 Europe Market Forecast, by End-user
11.8.1 Hospitals
11.8.2 Aesthetic Clinics & Dermatology Centers
11.8.3 Others
11.9 Market Analysis, by Country
11.10 Market Value Share Analysis, by Country
11.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
11.11.1 Germany
11.11.2 France
11.11.3 U.K.
11.11.4 Italy
11.11.5 Spain
11.11.6 Rest of Europe
11.12 Market Attractiveness Analysis
11.12.1 By Treatment Type
11.12.2 By Disease Indication
11.12.3 By End-user
11.12.4 By Country

Section 12: Asia Pacific Hyperpigmentation Disorders Treatment Market Analysis
12.1 Key Findings
12.2 Asia Pacific Hyperpigmentation Disorders Treatment Market Overview
12.3 Asia Pacific Market Value Share Analysis, by Treatment Type
12.4 Asia Pacific Market Forecast, by Treatment Type
12.4.1 Topical Drugs
12.4.2 Laser Therapy
12.4.3 Chemical Peels
12.4.4 Microdermabrasion
12.4.5 Phototherapy
12.4.6 Others
12.5 Asia Pacific Market Value Share Analysis, by Disease Indication
12.6 Asia Pacific Market Forecast, by Disease Indication
12.6.1 Melasma
12.6.2 Post-inflammatory Hyperpigmentation
12.6.3 Solar Lentigines
12.6.4 Others
12.7 Asia Pacific Market Value Share Analysis, by End-user
12.8 Asia Pacific Market Forecast, by End-user
12.8.1 Hospitals
12.8.2 Aesthetic Clinics & Dermatology Centers
12.8.3 Others
12.9 Market Analysis, by Country
12.10 Market Value Share Analysis, by Country
12.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
12.11.1 China
12.11.2 Japan
12.11.3 India
12.11.4 Australia & New Zealand
12.11.5 Rest of Asia Pacific
12.12 Market Attractiveness Analysis
12.12.1 By Treatment Type
12.12.2 By Disease Indication
12.12.3 By End-user
12.12.4 By Country

Section 13: Latin America Hyperpigmentation Disorders Treatment Market Analysis
13.1 Key Findings
13.2 Latin America Hyperpigmentation Disorders Treatment Market Overview
13.3 Latin America Market Value Share Analysis, by Treatment Type
13.4 Latin America Market Forecast, by Treatment Type
13.4.1 Topical Drugs
13.4.2 Laser Therapy
13.4.3 Chemical Peels
13.4.4 Microdermabrasion
13.4.5 Phototherapy
13.4.6 Others
13.5 Latin America Market Value Share Analysis, by Disease Indication
13.6 Latin America Market Forecast, by Disease Indication
13.6.1 Melasma
13.6.2 Post-inflammatory Hyperpigmentation
13.6.3 Solar Lentigines
13.6.4 Others
13.7 Latin America Market Value Share Analysis, by End-user
13.8 Latin America Market Forecast, by End-user
13.8.1 Hospitals
13.8.2 Aesthetic Clinics & Dermatology Centers
13.8.3 Others
13.9 Market Analysis, by Country
13.10 Market Value Share Analysis, by Country
13.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
13.11.1 Brazil
13.11.2 Mexico
13.11.3 Rest of Latin America
13.12 Market Attractiveness Analysis
13.12.1 By Treatment Type
13.12.2 By Disease Indication
13.12.3 By End-user
13.12.4 By Country

Section 14: Middle East & Africa Hyperpigmentation Disorders Treatment Market Analysis
14.1 Key Findings
14.2 Middle East & Africa Hyperpigmentation Disorders Treatment Market Overview
14.3 Middle East & Africa Market Value Share Analysis, by Treatment Type
14.4 Middle East & Africa Market Forecast, by Treatment Type
14.4.1 Topical Drugs
14.4.2 Laser Therapy
14.4.3 Chemical Peels
14.4.4 Microdermabrasion
14.4.5 Phototherapy
14.4.6 Others
14.5 Middle East & Africa Market Value Share Analysis, by Disease Indication
14.6 Middle East & Africa Market Forecast, by Disease Indication
14.6.1 Melasma
14.6.2 Post-inflammatory Hyperpigmentation
14.6.3 Solar Lentigines
14.6.4 Others
14.7 Middle East & Africa Market Value Share Analysis, by End-user
14.8 Middle East & Africa Market Forecast, by End-user
14.8.1 Hospitals
14.8.2 Aesthetic Clinics & Dermatology Centers
14.8.3 Others
14.9 Market Analysis, by Country
14.10 Market Value Share Analysis, by Country
14.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
14.11.1 GCC Countries
14.11.2 South Africa
14.11.3 Rest of Middle East & Africa
14.12 Market Attractiveness Analysis
14.12.1 By Treatment Type
14.12.2 By Disease Indication
14.12.3 By End-user
14.12.4 By Country

Section 15: Competition Landscape
15.1 Competition Matrix
15.2 Hyperpigmentation Disorders Treatment Market Share Analysis, by Company (2017)
15.3 Company Profiles
15.3.1 Bayer AG
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.1.4 Strategic Overview
15.3.1.5 Financial Overview
15.3.2 ALLERGAN
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2 Product Portfolio
15.3.2.3 SWOT Analysis
15.3.2.4 Strategic Overview
15.3.2.5 Financial Overview
15.3.3 Galderma S.A. (Nestle Skin Health S.A)
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.3.4 Strategic Overview
15.3.4 SkinCeuticals
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.4.4 Strategic Overview
15.3.5 Pierre Fabre
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.5.4 Strategic Overview
15.3.5.5 Financial Overview
15.3.6 EpiPharm AG
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2 Product Portfolio
15.3.6.3 SWOT Analysis
15.3.6.4 Strategic Overview
15.3.7 RXi Pharmaceuticals Corporation
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2 Product Portfolio
15.3.7.3 SWOT Analysis
15.3.7.4 Strategic Overview
15.3.7.5 Financial Overview
15.3.8 Obagi Cosmeceuticals LLC (Obagi medical)
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2 Product Portfolio
15.3.8.3 SWOT Analysis
15.3.8.4 Strategic Overview
15.3.9 Vivier Pharma
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2 Product Portfolio
15.3.9.3 SWOT Analysis
15.3.9.4 Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111996/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi